News - DelveInsight Business Research

von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

von-willebrand-disease-vwd-market

Von Willebrand disease is a type of blood disorder that causes the blood to clot improperly. Blood contains numerous proteins that aid in blood clotting when necessary. Von Willebrand factor is one of these proteins (VWF). VWD patients have either a low level of VWF in their blood or the VWF protein does not function… Continue reading von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Analyzing the Key Companies and the Emerging Gene Therapy in the Dermatology Segment

companies-in-gene-therapy-for-dermatology

Advances in genetics research have sparked a surge in interest in gene therapy in dermatology in recent years. Dermatology treatment options have expanded beyond topical drugs to include oral medications, injectables, and light and laser therapy. Now, rather than simply treating symptoms, gene therapy in dermatology offers a new path to address the root of… Continue reading Analyzing the Key Companies and the Emerging Gene Therapy in the Dermatology Segment

Hologic to acquire Bolder Surgical; Breakthrough Device Designation to Biological Dynamics; Luminopia declares FDA approval; HistoSonics secures Breakthrough Device Designation; Phillips-Medisize expands worldwide; PolyNovo launches NovoSorb BTM tech

medtech-news-for-hologic-luminopia-histosonics-phillips-polynovo

Hologic to acquire Bolder Surgical for USD160 Million, expanding its Surgical Franchise  On October 14, 2021, Hologic, Inc., a global player in women’s health, signed a definitive agreement to acquire Bolder Surgical. This US-based company offers advanced energy vessel sealing surgical devices for approximately USD 160 million. Essex Mitchell, Hologic’s Division President, Surgical, said that… Continue reading Hologic to acquire Bolder Surgical; Breakthrough Device Designation to Biological Dynamics; Luminopia declares FDA approval; HistoSonics secures Breakthrough Device Designation; Phillips-Medisize expands worldwide; PolyNovo launches NovoSorb BTM tech

Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies

Learning-Disabilities-severity-causes-types-treatment-technology-key-companies

Learning Disability, a neurological condition affects a significant population worldwide. It can be of various types and hampers the affected persons’ psychological and social relationships. To tackle the rising prevalence, prominent tech companies are actively exploring assistive digital tools and technologies for different learning disabilities.

Biogen’s ALS drug Tofersen (BIIB067); Phathom’s erosive esophagitis drug trial; Vertex’s islet cell therapy; Natera launches lung DNA test

recent-pharma-news-for-biogen-phathom-vertex-natera

Biogen’s tofersen fails to meet the primary goal in the Phase III ALS trial Biogen has announced that its investigational antisense drug, tofersen (BIIB067), flunked to meet the primary goal of Phase III VALOR clinical trial in superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) patients. Although the drug did not reach the primary goal,… Continue reading Biogen’s ALS drug Tofersen (BIIB067); Phathom’s erosive esophagitis drug trial; Vertex’s islet cell therapy; Natera launches lung DNA test

Development of Gene Therapies in Dermatology

gene-therapies-in-dermatology

What is Gene Therapy and Is the Skin Suitable for Gene Therapy? Since its first discovery, conceptualization in 1972, and successful application in 1990 by W. French Anderson, gene therapy has been a revolutionary game-changer in the field of biotechnology and healthcare. Now, its scope reaches beyond autoimmune disorders or cancer treatment, and potential genetic… Continue reading Development of Gene Therapies in Dermatology

Mapping the Increasing Burden of Heart Failure: What Does it Bring for Healthcare Market Companies?

heart-failure-market

Heart failure (HF), also referred to as Congestive Heart failure (CHF), is a condition in which the heart muscle fails to pump blood as efficiently as it should. This causes an accumulation of blood and fluid in the lungs, resulting in shortness of breath. Certain heart conditions, such as narrowed arteries in the heart (coronary… Continue reading Mapping the Increasing Burden of Heart Failure: What Does it Bring for Healthcare Market Companies?

Bausch + Lomb’s LuxSmart Intraocular Lenses; Movair’s Luisa Life Supporting Ventilator; Cochlear’s Nucleus and Baha Systems; Laborie Acquires Pelvalon; Know Labs’s SARS-CoV-2 Research; Syntellix’s MAGNEZIX;

medtech-news-updtes-updates-for-syntellix-bausch-lomb-movair-cochlear-laborie

Syntellix obtains product approval for India On October 07, 2021, Syntellix obtained the license to bring five different product families of its revolutionary bioabsorbable magnesium-based implants to market from India’s Central Drugs Standard Control Organisation (CDSCO) for the Indian market. With this approval, the company’s global market access and the number of potential patients treated… Continue reading Bausch + Lomb’s LuxSmart Intraocular Lenses; Movair’s Luisa Life Supporting Ventilator; Cochlear’s Nucleus and Baha Systems; Laborie Acquires Pelvalon; Know Labs’s SARS-CoV-2 Research; Syntellix’s MAGNEZIX;

Analysing the Treatment Approaches in the Hearing Loss Market and Key Companies in the Domain

hearing-loss-treatment-market

Hearing Loss is a severe condition that has a multifaceted impact on the individual’s growth and development. It can lead to isolation and loneliness and can also significantly reduce the quality of life. As per the WHO, nearly 430 million people (representing over 5% of the world’s population) require rehabilitation to address their ‘disabling’ hearing… Continue reading Analysing the Treatment Approaches in the Hearing Loss Market and Key Companies in the Domain

Brickell to Submit New Drug Application to FDA; Twin Health Raises $140M; BMS’ Deucravacitinib; Lando Biopharma’s LABP-104 gets Approval; NIH Grant of $ 3 M to Amydis; FDA Grant to GenSight’ GS030

recent-biotech-pharma-news-for-brickell-bms-amydis-gensight-cybrexa

Brickell Plans to Submit New Drug Application to FDA for gel Brickell Biotech will request the FDA in mid-2022 to approve its gel for excessive underarm sweating after decreasing sweat production and disease severity in two pivotal trials.  The gel achieved statistical significance in lessening the severity of hyperhidrosis and the amount of sweat produced… Continue reading Brickell to Submit New Drug Application to FDA; Twin Health Raises $140M; BMS’ Deucravacitinib; Lando Biopharma’s LABP-104 gets Approval; NIH Grant of $ 3 M to Amydis; FDA Grant to GenSight’ GS030